Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +5.22%48 Current Ratio is 5.92 as of Mar. 2026, which is 9% below its 10-year median of 6.47. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, RUA Life Sciences ranks better than 82.88% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. RUA Life Sciences's current ratio for the quarter that ended in Mar. 2026 was 5.92.
RUA Life Sciences has a current ratio of 5.92. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for RUA Life Sciences's Current Ratio or its related term are showing as below:
FRA:AOHA'
s Current Ratio Range Over the Past 10 Years
Min: 1.67 Med: 6.47 Max: 67.29
Current: 5.92
During the past 13 years, RUA Life Sciences's highest Current Ratio was 67.29. The lowest was 1.67. And the median was 6.47.
FRA:AOHA's Current Ratio is ranked better than 82.88% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs FRA:AOHA: 5.92
RUA Life Sciences (FRA:AOHA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
RUA Life Sciences Current Ratio Related Terms
RUA Life Sciences Current Ratio Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, RUA Life Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) has a Current Ratio of 5.92 as of Mar. 2026. This is near median its historical median of 6.47. Over the past decade, RUA Life Sciences' Current Ratio has ranged from 1.67 to 67.29. According to the industry distribution chart, RUA Life Sciences ranks #146 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 17.1%.
Is RUA Life Sciences' Current Ratio too high?
RUA Life Sciences' current Current Ratio of 5.92 is near median its 10-year median of 6.47. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 67.29. The Medical Devices & Instruments industry median Current Ratio is 2.49. RUA Life Sciences' value of 5.92 is 137.8% above this industry median. Based on the distribution chart, RUA Life Sciences ranks #146 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #146 out of 853 companies for Current Ratio. This places RUA Life Sciences in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. RUA Life Sciences' value of 5.92 is 137.8% above this benchmark. Historically, RUA Life Sciences' own Current Ratio has ranged from 1.67 to 67.29 over the past decade. While the company's 10-year median is 6.47 vs. the industry median of 2.49, RUA Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RUA Life Sciences's current Current Ratio of 5.92 is 137.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Current Ratio is 5.92, which is near median its own 10-year median of 6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current Current Ratio is 5.92, which is near median its 10-year median of 6.47 and 137.8% above the Medical Devices & Instruments industry median of 2.49. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Current Ratio is 5.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Current Ratio: 5.92 (near median its 10-year median of 6.47)
GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
Industry Position: 137.8% above the Medical Devices & Instruments median (#146 of 853)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
